Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hong Yeol | - |
dc.contributor.author | Son, Sejin | - |
dc.contributor.author | Lee, So Jin | - |
dc.contributor.author | You, Dong Gil | - |
dc.contributor.author | Yhee, Ji Young | - |
dc.contributor.author | Park, Jae Hyung | - |
dc.contributor.author | Swierczewska, Maggie | - |
dc.contributor.author | Lee, Seulki | - |
dc.contributor.author | Kwon, Ick Chan | - |
dc.contributor.author | Kim, Sun Hwa | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.contributor.author | Pomper, Martin G. | - |
dc.date.accessioned | 2021-09-05T03:06:18Z | - |
dc.date.available | 2021-09-05T03:06:18Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-11-03 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96803 | - |
dc.description.abstract | Conventional chemotherapy is plagued with adverse side effects because cancer treatments are subject to numerous variations, most predominantly from drug resistance. Accordingly, multiple or multistage chemotherapeutic regimens are often performed, combining two or more drugs with orthogonal and possibly synergistic mechanisms. In this respect, glycol chitosan (GC)-based nanoparticles (CNPs) serve as an effective platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy by overcoming resistance. Herein, DOX-encapsulated CNPs (DOX-CNPs) or Bcl-2 siRNA-encapsulated CNPs (siRNA-CNPs) exhibited similar physicochemical properties, including size, surface properties and pH sensitive behavior, regardless of the different physical features of DOX and Bcl-2 siRNA. We confirmed that the CNP platform applied to two different types of drugs results in similar in vivo biodistribution and pharmacokinetics, enhancing treatment in a dose-dependent fashion. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | TUMOR-BEARING MICE | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | EFFICACY | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | MICROENVIRONMENT | - |
dc.subject | RESISTANCE | - |
dc.subject | CISPLATIN | - |
dc.subject | MODELS | - |
dc.subject | CELLS | - |
dc.title | Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: Sequential delivery of doxorubicin and Bcl-2 siRNA | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Ick Chan | - |
dc.identifier.doi | 10.1038/srep06878 | - |
dc.identifier.scopusid | 2-s2.0-84930683143 | - |
dc.identifier.wosid | 000344227500001 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.4 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 4 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | TUMOR-BEARING MICE | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | MICROENVIRONMENT | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | MODELS | - |
dc.subject.keywordPlus | CELLS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.